ArticleBMC genomics2025
Comprehensive genomic analysis of clinical Serratia marcescens isolates unveils extensive dissemination and genetic context of co-occurring of bla
Article in BMC genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSerratia marcescens has emerged as an important multidrug-resistant pathogen implicated in hospital-acquired infections. However, detailed genomic insights into the genetic contexts and dissemination mechanisms of carbapenemase and extended-spectrum β-lactamase (ESBL) genes in this species remain limited. This study aimed to elucidate the genomic features and evolutionary relationships among clinical S. marcescens isolates harboring carbapenem and ESBL resistance determinants.
resultsWe conducted whole-genome sequencing and comparative genomic analyses of 11 clinical multidrug-resistant S. marcescens isolates from a tertiary hospital in eastern China. Two isolates (YQ11402 and YQ114022) concurrently harbored the carbapenemase gene blaKPC-2 and the ESBL gene blaCTX-M-14, predominantly located within IS26-associated composite mobile genetic elements on conserved IncR and IncFII-type plasmids. These isolates exhibited extensive co-resistance to aminoglycosides, fluoroquinolones, and tetracyclines mediated by additional plasmid-borne genes such as aac(6′)-Ic, oqxAB, qnrS1, and tet(41). Comparative analysis revealed significant genetic similarity (> 99% nucleotide identity) between resistance plasmids identified in S. marcescens and those previously reported in Klebsiella pneumoniae and Escherichia coli, underscoring interspecies dissemination. Phylogenomic analysis using average nucleotide identity (ANI) indicated clonal relationships among the majority of isolates, highlighting potential intra-hospital transmission events.
conclusionsOur findings reveal that clinical isolates of S. marcescens act as reservoirs for high-risk resistance genes, notably blaKPC-2 and blaCTX-M-14, located on highly conserved and transmissible plasmid backbones. These results underscore the critical need for genomic surveillance to monitor this pathogen's role in resistance dissemination, thereby informing more effective infection prevention and antimicrobial stewardship practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.